Abstract
INVESTIGATIONS made to determine the causes of loss of antihæmophilic factor (AHF) during the Blombäck process1 for preparing AHF-rich fibrinogen from large volumes of plasma have revealed that when the starting material is frozen plasma instead of fresh plasma there is a presumed liability which can be converted to an advantage.
Similar content being viewed by others
Article PDF
References
Blombäck, M., Arkiv. Kemi, 12, 387 (1958).
McMillan, C. W., Diamond, L. K., and Surgenor, D. M., New England J. Med., 265, 224 (1961).
Ninth Cong. Intern. Soc. Blood Transfusion, Mexico City (1962).
Pool, J. G., and Robinson, J., Brit. J. Hæmat., 5, 24 (1959).
Pool, J. G., and Robinson, J., Brit. J. Hæmat., 5, 17 (1959).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
POOL, J., HERSHGOLD, E. & PAPPENHAGEN, A. High-potency Antihæmophilic Factor Concentrate prepared from Cryoglobulin Precipitate. Nature 203, 312 (1964). https://doi.org/10.1038/203312a0
Issue Date:
DOI: https://doi.org/10.1038/203312a0
This article is cited by
-
Novel characteristics of soluble fibrin: hypercoagulability and acceleration of blood sedimentation rate mediated by its generation of erythrocyte-linked fibers
Cell and Tissue Research (2022)
-
Prevention and Management of Bleeding Episodes in Children with Hemophilia
Pediatric Drugs (2018)
-
The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotropic liver transplantation
Hepatology International (2013)
-
Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia
Molecular Therapy (2011)
-
General Surgery in Patients With a Bleeding Diathesis: How We Do It
World Journal of Surgery (2011)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.